RADIOLABELLED ANTIBODY THERAPY OF ACUTE LEUKEMIA

急性白血病的放射性标记抗体治疗

• 批准号: 6102380
• 负责人: FREDERICK APPELBAUM
• 金额: $ 40.93万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-12 至 2000-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6102380
• 关键词: Macaca nemestrina; acute lymphocytic leukemia; acute myelogenous leukemia; acute nonlymphocytic leukemia; autologous transplantation; bone marrow transplantation; busulfan; clinical trials; colony stimulating factor; combination cancer therapy; cyclophosphamide; dogs; drug adverse effect; human subject; human therapy evaluation; interleukin 3; iodine; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide therapy; nuclear medicine; radiation therapy dosage; radionuclides; radiopharmacology; whole body irradiation dosage

The overall goal of project III is to evaluate the use of I-131- labeled anti-myeloid antibodies and autologous marrow transplantation as treatment for acute nonlymphocytic leukemia. This approach is based on the ability of labeled antibody to localize to the marrow space and the utility of external beam total body irradiation (TBI) with autologous marrow transplantation in treating ANL. We will initially measure the pharmacokinetics, biodistribution and associated radiation dosimetry of varying doses of I-131-labeled anti-myeloid antibodies in patients with ANL in second (or subsequent) remission. In patients in whom we achieve favorable dosimetry, we will evaluate the effects of increasing therapeutic doses of I- 131-labeled antibody with particular attention to the ability of the antibody-conjugate to ablate marrow, recovery of hematopoiesis following autologous transplantation, and the nature and extent of extramedullary toxicities. If favorable dosimetry is not achieved we will evaluate alternatives antibodies, forms of antibody (F(ab) or F(ab')2), or antibody infusion schedules.

项目 III 的总体目标是评估 I-131-的使用情况 标记的抗骨髓抗体和自体骨髓 移植作为治疗急性非淋巴细胞白血病的方法。 该方法基于标记抗体的能力 定位到骨髓空间和外束的效用 自体骨髓全身照射 (TBI) 移植治疗ANL。 我们将首先测量 药代动力学、生物分布和相关辐射 不同剂量 I-131 标记的抗髓细胞药物的剂量测定 第二次（或后续）ANL 患者体内出现抗体 缓解。 在我们获得良好剂量测定的患者中， 我们将评估增加 I- 治疗剂量的效果 特别注意131标记抗体的能力 抗体缀合物消融骨髓，恢复 自体移植后的造血作用 髓外毒性的性质和程度。 如果有利的话 未实现剂量测定，我们将评估替代方案 抗体、抗体形式（F(ab) 或 F(ab')2）或抗体 输液时间表。